Choosing the right CDMO for bile acids is a more nuanced decision than selecting a general pharmaceutical contract manufacturer. Bile acid molecules are chemically complex, derived from regulated animal-sourced raw materials, and subject to a distinct regulatory framework that requires specialist knowledge to navigate. As bile acid-based drug development continues to expand, with a growing pipeline of FXR agonists, TGR5-targeting therapies, and novel formulation approaches, the demand for experienced CDMOs in this space is increasing.
This guide sets out the key criteria pharmaceutical companies should apply when evaluating a CDMO for bile acids. It is worth noting that ICE Pharma’s own CDMO offer is specifically for finished dosage form (FDF) manufacture, complementing its position as a leading global supplier of bile acid APIs. This distinction is relevant context for how the criteria below apply to different types of partnership.
Why Bile Acids Require Specialist CDMO Expertise
Not every CDMO is equipped to handle bile acids. The molecule class presents a set of challenges that distinguish it clearly from standard small-molecule API manufacturing.
First, the raw material starting point is biological. Bile acids are derived from animal bile, typically from bovine, chicken, porcine, or ovine sources, as a by-product of the meat processing industry. Working with animal-derived starting materials introduces requirements around supplier qualification, veterinary certification, traceability, and TSE (transmissible spongiform encephalopathy) risk management that a generalist chemical API manufacturer may not have in place.
Second, the chemistry is demanding. Bile acids share a four-ring steroid backbone and differ from one another primarily through the number, position, and orientation of hydroxyl groups. Converting one bile acid to another, for example epimerising chenodeoxycholic acid (CDCA) to produce ursodeoxycholic acid (UDCA), requires regioselective chemistry under tightly controlled conditions. Achieving consistent stereoselectivity and separating structurally similar epimeric impurities to pharmacopoeial purity standards is a challenge that demands genuine process expertise, not generic organic chemistry capability.
Third, bile acid-derived products are subject to regulatory scrutiny from multiple angles: as animal-derived pharmaceutical intermediates, as chemically synthesised APIs, and in many cases as finished dosage forms intended for markets with differing regulatory requirements. A CDMO without deep familiarity with the relevant ICH guidelines, pharmacopoeial standards, and market-specific health authority expectations will be poorly placed to support registration and approval of bile acid products.
1. Depth of Bile Acid-Specific Scientific Knowledge
The first and most fundamental criterion is scientific depth in bile acid chemistry and pharmacology. This is not a category where generalist capability is sufficient.
A qualified bile acid CDMO should be able to demonstrate:
- A thorough understanding of bile acid chemistry, including steroid ring structure, hydroxyl group orientation, conjugation chemistry, and the physicochemical differences between primary, secondary, and tertiary bile acids
- Practical experience in the key transformation reactions used in bile acid synthesis, including selective oxidation, stereoselective reduction, hydrolysis, and conjugation
- Knowledge of bile acid receptor biology, including FXR, TGR5, and related receptors, relevant to the pharmacological rationale behind the molecule being developed
- Familiarity with bile acid applications as both active pharmaceutical ingredients and as excipients in drug delivery, where their amphipathic properties are exploited to enhance solubility and bioavailability of poorly soluble drugs
This last point is increasingly relevant. As research has demonstrated, bile acids act as both drug solubilising and permeation-modifying agents, improving the bioavailability of drugs that would otherwise be limited by poor aqueous solubility or low membrane permeability. A CDMO with expertise in bile acid formulation science is better placed to help sponsors exploit these properties in finished dosage form development. ICE Pharma’s Chief Commercial Officer, Roger Viney, has discussed this publicly, noting that bile acids are endogenous and therefore reprocessed by the liver after use, and that the range of bile acid structures available provides formulation scientists with versatile tools to address different drug delivery challenges.
2. Integrated Supply Chain: From Bile Collection to Finished Product
One of the most important structural questions to ask of any CDMO for bile acids is how far up the supply chain their control extends. There is a significant difference between a CDMO that purchases commercially available bile acid intermediates and one that controls production from raw bile collection through to the finished API or formulated product.
An integrated supply chain offers several advantages that matter directly to pharmaceutical customers:
- Traceability: Where raw bile is the true starting material, end-to-end traceability from source animal to finished API is both a regulatory requirement and a quality assurance imperative. A CDMO that manufactures from bile they source and process themselves can provide this traceability without relying on documentation from third-party suppliers who may not be subject to equivalent quality standards.
- Supply security: A fragmented supply chain, with multiple independent intermediaries between raw bile and finished API, introduces points of failure and opacity. An integrated manufacturer can respond more rapidly to supply disruptions, maintain buffer stocks at multiple stages, and provide customers with genuine security of supply.
- Quality consistency: When the same organisation controls every transformation step, in-process quality decisions are coherent and cumulative. A CDMO relying on purchased intermediates has limited visibility of the quality decisions made upstream, which can result in batch-to-batch variability that is difficult to diagnose or control.
- Regulatory simplicity: From a Drug Master File (DMF) perspective, a single integrated manufacturer can cover all manufacturing stages within one filing, simplifying the customer’s registration dossier and reducing the number of parties a regulatory authority must assess.
ICE Pharma’s position as a leading global integrated producer of UDCA reflects over 70 years of exactly this kind of vertical integration. The group controls its supply chain from bile collection through to finished dosage form manufacture, with all steps subject to a harmonised quality management system and supported by a global manufacturing network spanning Europe, Asia, Latin America, and Oceania.
3. Regulatory Credentials and Multi-Market Authorisation
The regulatory dimension of bile acid CDMO selection deserves careful scrutiny. Bile acid APIs are subject to ICH Q7 (the international GMP standard for active pharmaceutical ingredients), which has been adopted by the FDA, EMA, PMDA, WHO, and other major regulatory bodies. For animal-derived starting materials, additional guidance applies, including EMA guidelines on minimising the risk of transmitting TSE agents, and requirements for documented veterinary oversight of source animals.
Beyond API manufacturing, a CDMO offering finished dosage form services must comply with the relevant GMP frameworks for drug product manufacturing in each target market. A CDMO authorised to manufacture for only one or two markets limits the commercial options available to their customers.
Key regulatory credentials to verify include:
- GMP authorisation from the relevant health authority for each market the customer intends to supply, which may include AIFA (Italy), FDA (USA), EMA (via EDQM), PMDA (Japan), Health Canada, CDSCO (India), MFDS (South Korea), Medsafe (New Zealand), and ANVISA (Brazil)
- A documented track record of successful regulatory inspections without major findings
- Experience supporting customers in regulatory submissions, dossier preparation, and market-specific product registration
- Pharmacopoeial compliance for bile acid API specifications, including European Pharmacopoeia (Ph. Eur.) and United States Pharmacopeia (USP) monographs for relevant bile acids
ICE Pharma’s manufacturing sites are regularly inspected and authorised by all of the above agencies. The group’s Quality and Compliance framework is harmonised globally, with a dedicated quality team that ensures consistency of standards across every production site and provides customers with regulatory filing support across all major pharmaceutical markets.
4. Finished Dosage Form Capability and Development Services
For many pharmaceutical companies, the goal is not simply to source a bile acid API, but to bring a bile acid-based medicine to market. A CDMO that can take a programme from API synthesis through formulation development, clinical trial supply, and commercial manufacture under one roof offers a compelling proposition in terms of efficiency, accountability, and speed to market.
When evaluating a CDMO’s finished dosage form capability for bile acid-based products, consider:
- The range of oral solid and liquid dosage forms the CDMO is authorised and equipped to produce, as UDCA and related bile acids are primarily administered orally
- Scale of production capacity relative to anticipated commercial demand
- The availability of clinical trial manufacturing services, including small-batch capability, comparator sourcing, and clinical packaging
- In-house analytical development and method validation capability, essential for demonstrating finished product quality and stability
- Regulatory affairs support for dossier preparation and variation management
ABC Farmaceutici, ICE Pharma’s Italian subsidiary established in 1925, is the group’s dedicated finished dosage form manufacturing and CDMO operation. It is important to note that ICE Pharma’s CDMO services are offered specifically through ABC at the FDF level. This means customers benefit from a partner who supplies the bile acid API and then, through ABC, develops and manufactures the finished product, providing genuine single-source accountability across the full product lifecycle. ABC occupies a 76,000 square metre facility near Turin, is fully GMP certified and inspected by AIFA and multiple international health authorities, and has a production capacity of over 40 million boxes of pharmaceutical dosages per year. Its CDMO service offering covers the full development and manufacturing lifecycle: formulation development of liquid and solid oral dosage forms, analytical method development and validation, manufacturing process development and scale-up, ICH stability studies, clinical trial manufacture, and regulatory dossier preparation in e-CTD format for multiple markets. The fact that ABC operates as part of a group that also manufactures bile acid APIs creates a genuine single-source capability that few CDMOs can match.
5. Research and Development Capability for Novel Bile Acid Entities
The bile acid pharmaceutical landscape is not static. Beyond established products like UDCA, there is a substantial and growing pipeline of novel bile acid-derived therapeutics, including FXR agonists, TGR5 agonists, bile acid conjugates, and modified bile acid structures targeting metabolic and liver disease indications. For pharmaceutical companies working in this space, the ability of a CDMO to support early-stage research and process development, not just commercial-scale manufacturing, is a genuine differentiator.
A CDMO with in-house research and development capability in bile acid chemistry can offer:
- Route scouting and process design for novel bile acid derivatives
- Development and optimisation of synthetic routes at laboratory and pilot scale
- Analytical method development for characterisation of novel structures
- Scale-up from gram to multi-tonne quantities with process validation
- Access to a library of reference bile acid structures for screening
ICE Pharma operates five R&D centres globally, with dedicated focus on bile acid science. New Zealand Pharmaceuticals (NZP), one of the group’s key subsidiaries, has developed a library of approximately 500 modified bile acid structures available for screening as potential drug candidates, with early-stage research focused on conditions including Alzheimer’s and Parkinson’s disease. The research chemicals catalogue accessible through the Bile Acids Expert platform provides academic and pharmaceutical researchers with access to human, animal species, and synthetic bile acids, their salts, and amino acid conjugates, from milligram to kilogram quantities.
6. Supply Chain Resilience and Global Footprint
A bile acid CDMO evaluated purely on technical and regulatory credentials may still fail a customer if it lacks the supply chain resilience to deliver reliably at commercial scale. The COVID-19 pandemic, and the supply chain disruptions that followed, brought the risks of geographic concentration and single-source dependency into sharp focus across the pharmaceutical industry.
When assessing supply chain resilience, consider:
- Whether the CDMO operates multiple manufacturing sites across different geographies, reducing the risk of a single site disruption affecting supply
- Whether raw bile is sourced from multiple species and regions, providing flexibility if one source is disrupted by disease, regulatory change, or trade restrictions
- The depth of inventory management and buffer stock practices
- The CDMO’s track record of on-time, in-full delivery to commercial customers
ICE Pharma’s interconnected network of seven manufacturing facilities across Europe, Latin America, Asia, and Oceania provides customers with genuine supply chain diversity. Bile-derived starting materials are processed at sites including NZP in New Zealand (bovine and ovine bile), Raichem in India (chicken bile, with newly expanded capacity of 120 metric tons per year of raw UDCA), and ICE Japan for the Japanese market. This multi-site, multi-species model is deliberately designed to mitigate supply concentration risk and maintain the security of supply that customers in regulated pharmaceutical markets require.
Choosing the Right Partner
Selecting a CDMO for bile acids is ultimately a decision about partnership as much as capability. The right partner will bring scientific depth, regulatory rigour, integrated manufacturing, and a genuine understanding of the unique challenges that bile acid-based development presents. They will be transparent about what they can and cannot do, responsive to evolving project needs, and equipped to support a programme from early development through to commercial launch and beyond.
The questions to ask are not simply “can you make this molecule?” but “do you understand its chemistry well enough to make it reliably, at scale, to the purity required, from traceable sources, in compliance with every market we intend to supply?”
ICE Pharma meets every criterion set out in this guide. With over 70 years of accumulated expertise in bile acid science, a fully integrated supply chain from bile collection to finished product, seven GMP-certified manufacturing sites across five continents, and authorisation from regulatory agencies including the FDA, EMA, PMDA, AIFA, Health Canada, and ANVISA, ICE Pharma is uniquely positioned to support bile acid-based drug development at any scale and stage. It is important to be clear about where our CDMO offer sits: ICE Pharma provides bile acid APIs as a global integrated manufacturer, and our dedicated CDMO services for finished dosage form development and manufacture are delivered through ABC Farmaceutici. This means customers can work with a single partner for both API supply and FDF development, with full support for analytical development, clinical trial supply, regulatory affairs, and technology transfer. Backed by five global R&D centres and a comprehensive library of over 500 bile acid structures, we bring the scientific and operational depth that bile acid-based drug development demands.
If you are evaluating a bile acid CDMO partner, we would welcome the conversation. Contact our team to discuss your project requirements, or explore our full range of pharmaceutical services to find out how ICE Pharma can support your programme.